» Articles » PMID: 7504271

Stable in Vivo Expression of the Cystic Fibrosis Transmembrane Conductance Regulator with an Adeno-associated Virus Vector

Overview
Specialty Science
Date 1993 Nov 15
PMID 7504271
Citations 145
Authors
Affiliations
Soon will be listed here.
Abstract

Adeno-associated virus (AAV) vectors expressing the normal cystic fibrosis transmembrane conductance regulator (CFTR) cDNA complement the cystic fibrosis (CF) defect in vitro. Unlike other DNA virus vectors, AAV is a stably integrating virus, which could make possible long-term in vivo complementation of the CF defect in the airway epithelium. We report AAV-CFTR gene transfer and expression after infection of primary CF nasal polyp cells and after in vivo delivery of AAV-CFTR vector to one lobe of the rabbit lung through a fiberoptic bronchoscope. In the rabbit, vector DNA could be detected in the infected lobe up to 6 months after administration. A 26-amino acid polypeptide sequence unique to the recombinant AAV-CFTR protein was used to generate both oligonucleotide probes and a polyclonal antibody which allowed the unambiguous identification of vector RNA and CFTR protein expression. With these reagents, CFTR RNA and protein were detected in the airway epithelium of the infected lobe for up to 6 months after vector administration. AAV vectors do, therefore, efficiently promote in vivo gene transfer to the airway epithelium which is stable over several months. These findings indicate that AAV-CFTR vectors could potentially be very useful for gene therapy.

Citing Articles

Effective Reduction of Transgene-Specific Immune Response With rAAV Vectors Co-Expressing miRNA-UL112-5p or ERAP1 shRNA.

Huang X, Wang X, Sun Y, Xie X, Xiao L, Xu Y J Cell Mol Med. 2025; 29(2):e70308.

PMID: 39823241 PMC: 11740984. DOI: 10.1111/jcmm.70308.


A Penetrable AAV2 Capsid Variant for Efficient Intravitreal Gene Delivery to the Retina.

He X, Fu Y, Xu Y, Ma L, Chai P, Shi H Invest Ophthalmol Vis Sci. 2025; 66(1):6.

PMID: 39745676 PMC: 11702840. DOI: 10.1167/iovs.66.1.6.


Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases.

Sussman C, Liberatore R, Drozdz M Pharmaceutics. 2024; 16(4).

PMID: 38675196 PMC: 11053842. DOI: 10.3390/pharmaceutics16040535.


Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights.

Lopez-Gordo E, Chamberlain K, Riyad J, Kohlbrenner E, Weber T Viruses. 2024; 16(3).

PMID: 38543807 PMC: 10975205. DOI: 10.3390/v16030442.


Delivery of Adeno-Associated Virus Vectors to the Central Nervous System for Correction of Single Gene Disorders.

Daci R, Flotte T Int J Mol Sci. 2024; 25(2).

PMID: 38256124 PMC: 10816966. DOI: 10.3390/ijms25021050.


References
1.
Blacklow N, HOGGAN M, Kapikian A, Austin J, Rowe W . Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol. 1968; 88(3):368-78. DOI: 10.1093/oxfordjournals.aje.a120897. View

2.
Hyde S, Gill D, Higgins C, Trezise A, MacVinish L, Cuthbert A . Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature. 1993; 362(6417):250-5. DOI: 10.1038/362250a0. View

3.
Samulski R, Chang L, Shenk T . Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 1989; 63(9):3822-8. PMC: 250975. DOI: 10.1128/JVI.63.9.3822-3828.1989. View

4.
Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

5.
Kotin R, SINISCALCO M, Samulski R, Zhu X, Hunter L, Laughlin C . Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A. 1990; 87(6):2211-5. PMC: 53656. DOI: 10.1073/pnas.87.6.2211. View